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To test the hypothesis that 9-cti-retinoic acid is a ligand for cellular retinoic acid binding protein II (CRABP II), human CRABP II was expressed 
as a glutathione-9transferase fusion protein (GST-CRABP II) and a single affinity purification step used to extract it from bacterial ysates. 
GST-CRABP II bound all trans-retinoic acid with high affinity (& 14.2 + 6.5 nM), but 9-ci.-retinoic acid bound poorly. These studies suggest 
that 9-cti-retinoic acid is not a ligand for CRABP II. Their ease of puritication makes GST-CRABP fusion proteins useful tools for ligand binding 
studies with different retinoids. 
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1. INTRODUCTION 
Cellular retinoic acid binding protein (CRABP) is a 
low molecular weight (M, = 16,000) cytoplasmic protein 
which binds all trans-retinoic acid with high affiity and 
is expressed in a variety of tissues [I]. Recently, two 
forms of CRABP have been identified [24]; while 
closely related in sequence they have distinct biophysi- 
cal properties and are reported to differ in their affinity 
for all trans-retinoic acid, with CRABP I having a 
higher affinity than CRABP II [5,6]. CRABP may be of 
critical importance in development by regulating the 
availability of all trans-retinoic acid to the nuclear reti- 
noic acid receptors (RARs). 
raises the possibility that CRABP II could be a specific 
9-cis-retinoic acid binding protein. To test this hypothe- 
sis, we have cloned the coding sequence for human 
CRABP II into an expression vector and expressed it in 
E. coli as a glutathione-S-transferase (GST) fusion pro- 
tein. We report the ligand binding properties of GST- 
CRABP II and show that, by comparison with all trans- 
retinoic acid, the 94s isomer displays a low aflinity for 
CRABP II. 
2. MATERIALS AND METHODS 
2.1. Retinoic acid 
RARs are ligand-dependent transcriptional regula- 
tors that bind all truns-retinoic acid with high affinity 
and represent a subset of the steroid/thyroid hormone 
receptor superfamily [7J A distinct yet closely related 
group of nuclear receptors, termed retinoid X receptors 
or RXRs [8], has been shown to bind 9-cis-retinoic acid 
[9,10]. RXRs have the potential to regulate diverse 
hormone-response pathways by acting as heterodimers 
with the nuclear receptors for thyroid hormone, vitamin 
D and all trans-retinoic acid [I I]. Thus, 9-cis-retinoic 
acid may be an important intracellular egulatory mole- 
cule, but very little is yet known of its pathways of 
synthesis, metabolism and transport within the cell. The 
fact that CRABP II apparently has a 15-fold lower 
affinity for all trans-retinoic acid than CRABP I [5] 
Stock solutions of all trans-retinoic acid (Sigma) and 9-cis-retinoic 
acid (a gift from Dr. M. Klaus, Hoffman-La Roche, Basel) were made 
up in ethanol assuming an extinction coefficient of 36,500 M-’ . cm-’ 
at 343 nm. The radiochemical purity of all truns-[1 l,lZ’IIlretinoic 
acid (49.3 Cilmmol, Du Pont-NEN, Stevenage, UK) was verified by 
isocratic elution (2 ml mitt-‘) from a 25 cm x 4.6 mm Zorbax-NH, (Du 
Pont) column in 9O:lO acetonitrile:dichloromethane, 10mM acetic 
acid. All manipulations of retinoic acid were done under darkroom- 
or dim-light conditions; stock solutions were stored at -20°C in the 
dark and used within 2-3 days. 
2.2. Cloning and sequence analysis of human CRABP II 
The CRABP II coding sequence was amplified from 1 ,ug total RNA 
from human retinoic acid-treated ennal fibroblasts [12]. cDNA was 
synthesised by adding RNA to 200 PM of each deoxynucleotide tri- 
phosphate, 0.32 pug oligo d(T) primer, 5 mM MgCl,, 2.5 U RNasin, 
and 15 U AMV reverse transcrintase (Promeea. Southamnton. UK) 
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in a total volume of 20 ~1, buffered Gith ma&al supplied with the 
enzyme. Incubation for 15 min at 42’C was followed by denaturation 
at 95“C, 10 min; after chilling on ice, 10 pl of the cDNA reaction was 
added to 100 pmol primer 1 (5’ATTCTAGATCCCCAACITCTC- 
TGGCAACTG 3’, XbaI site underlined, initiation ATG in bold), 100 
pmol primer 2 (5’CTGGATCCXCACTCTCGGACGTAGACCCT- 
G3’, BarnHI site underlined, stop codon in bold), 2 mM MgCl,, and 
2.5 U Taq polymerase (Perkin-Elmer-Cetus) in a total volume of 100 
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~1 containing buffer supplied with the enzyme. Amplification was for 
30 cycles of denaturation at 95°C (30 s), annealing at 55’C (30 s) and 
extension at 72OC (42 s). Primer sequences were based on the human 
CRABP II sequence reported by Eller et al [3]. PCR products (ca. 420 
bp) were digested with XbaI and BumHI and cloned into Bluescript. 
The CRABP II cDNA sequence was verified by sequencing the insert 
in both directions with an Applied Biosystems DNA sequencer. 
CRABP II was re-amplified from the plasmid with new primers to 
incorporate BurnHI and EcoRI sites (primer 3: S’end, SACT- 
GGATCCATCCCCAACTTCTCTGGCAAC 3’, BarnHI site; primer 
4: 3’ end, SGATGAATTCCTCACTCICGGACGTAGAC3’, EcoRI 
site) and subcloned into the pGEX-2T vector at the BamHUEcoRI 
sites in-frame with the GST coding sequence and immediately down- 
stream of the thrombin cleavage site; cleavage of the GST-CRABP II 
fusion protein with thrombin will thus yield a CRABP II peptide with 
a Gly-Ser amino-terminal extension. Recombinant plasmid (pG- 
CRABP2) was transformed into E. coli DH5a and the expression of 
GST-CRABP II fusion protein verified by SDS-PAGE [ 131: overnight 
cultures in LB medium [14] containing 50 pg . ml-’ ampicillin were 
diluted 1: 10 with fresh medium, isopropyl-/I-o-thiogalactopyranoside 
(IPTG, Sigam) was added to 0.1 mM 1 h later and the cells harvested 
after a further 4 h at 37’C [15]. 
2.3. Extraction and affinity gel purification of GST-CRABP II fusion 
protein 
GST-CRABP II fusion protein was extracted from 1 1 cultures as 
described by Quinn et al. [15]. Briefly, after induction of fusion protein 
with IPTG (as above), cells were harvested, washed with 25% w/v 
sucrose, 10 mM EDTA, 0.1 mM PMSF, 50 mM Tris-HCl, pH 8.0 
(buffer A), and resuspended in 40 ml buffer A containing 2 mg . ml-’ 
lysozyme. After 1 h on ice, cells were resuspended in 20 ml 14 mM 
Na,HPOJ8 mM KH*PO,, pH 7.0 (buffer B), and lysed by freeze- 
thawing twice. Bacterial debris was removed by centrifugation and the 
lysate mixed with 5 ml GSH-Sepharose 6B beads (50% v/v) [16], for 
l-2 h at 4°C. Beads carrying adsorbed fusion protein were spun down 
(1 000 x g, 1 min at 4’C) and washed 5 times with buffer B and once 
in 50 mM Tris-HCI, pH 8.0. Fusion protein was eluted by resuspend- 
ing the beads for 1 h at room temperature in an equal volume of 10 
mM GSH, 50 mM Tris-HCl, pH 8.0. The supematant was concen- 
trated by ultrafiltration through Centricon 10 U (Amicon, 
Stonehouse, UK) and the fusion protein stored at -20°C either frozen 
or in 50% glycerol. As a control for experiments with the GST- 
CRABP II fusion protein, GST protein was extracted as above from 
IPTG-induced cultures of E. coli DH5a carrying the pGEX-2T plas- 
mid. 
Cleavage of the fusion protein was by incubation, either in solution 
or bound to the GSH affinity gel beads, for 1 h at room temperature 
with an excess (10 U . ml-’ beads or 0.17 U . pg-’ fusion protein) of 
thrombin (Calbiochem, 3554 U . mg-‘) in 150 mM NaCl, 2.5 mM 
CaCl,, 0.1% 2-mercaptoethanol, 50 mM Tris-HCl, pH 8.0 (buffer C). 
2.4. Protein estimation and SDS-PAGE 
Protein concentrations were estimated from BSA standards (Sigma) 
using the Bradford method [17]. 15% acrylamide gels (0.75 mm thick) 
were run to a length of 6 cm using the Laemmli buffer system [13]. Gels 
were fixed and stained with 0.05% Coomassie blue in 20% methanol, 
10% acetic acid. 
2.5. High performance size-exclusion chromatography (HPSEC) 
HPSEC of aN trans-[1 1,12-31-@etinoic acid bound to fusion protein 
was by elution (1 ml min-‘) from a Phenomenenex (Macclesfield, 
UK) Biosep SEC S3000 column (300 x 4.6 mm) in 50 mM sodium 
phosphate buffer, pH 6.8, at room temperature. Eluate fractions were 
collected for scintillation counting. 
2.6. Fluorimetric titration 
The binding of retinoic acid to GST-CRABP II fusion protein, 
cleaved CRABP II and GST protein was monitored by fluorimetric 
titration [18,19] at room temperature with a Kontron SFM 25 fluori- 
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meter set to excitation and emission wavelengths of 350 and 475 nm, 
respectively. Retinoic acid was added in ethanol (l-2 ,ul per addition) 
to 2 ml 0.2-l PM GST-CRABP II fusion protein, 50 mM Tris-HCl, 
pH 7.5, in borosilicate glass tubes, and mixed by inversion. After each 
addition, the ligand was allowed to bind for 5 min before inserting the 
tube into the fluorimeter. Once the fluorimeter eading had stabilised 
(ca. 6 s), the mean fluorescence over two consecutive 8-s periods was 
recorded using the integrator. Fluorescence readings were stable over 
this period but declined with longer exposure in the fluorimeter; tubes 
were thus exposed to UV within the fluorimeter for the shortest pos- 
sible time. The final ethanol concentration was less than 1%. To 
compare the binding of aN tram- and 9-cis-retinoic acid, a different 
approach was used to minimise the possibility of UV-induced 
cis-+truns isomerization of 9-cis-retinoic acid: retinoic acid at an in- 
creasing concentration was added to each of a series of tubes contain- 
ing 1.2 ml GST-CRABP II fusion protein in 50 mM Tris-HCI, pH 7.5, 
and the fluorescence recorded once for each tube after allowing the 
ligand to bind for > 5 min. Binding affinity for the ligand was esti- 
mated by plotting aPO against (a/l-a)& where PO is binding protein 
concentration (M), & is retinoid concentration (M) and a is F,,,-FI 
F,,,,,-F, where F,,, is the maximum fluorescence intensity (at satura- 
tion), F, is the initial fluorescence intensity in the absence of retinoic 
acid and F is the fluorescence intensity at a particular R,, [18,19]. 
Excitation and emission spectra were recorded in 50 mM Tris-HCl, 
pH 7.5, using a quartz cell in a Perkin-Elmer LC3 fluorimeter. 
3. RESULTS 
3.1. Expression of human CRABP II as a GST fusion 
protein 
The 422 bp human CRABP II cDNA amplified from 
fibroblast RNA extended from the ATG initiation 
codon to the TGA stop and the nucleotide sequence was 
identical to that previously reported for human CRABP 
II [3,4] but with two exceptions: a G replacing an A at 
:: 
3, 
6i 
Md e 
Fig. 1. SDS-PAGE (15% acrylamide) of affinity-purified GST- 
CRABP II. Track: (a) GST-CRABP II fusion protein from pG- 
CRABP2 transformants after elution from affinity gel; (b) thrombin 
cleavage products from GST-CRABP II bound to affinity gel; (c) 
affinity-purified GST expressed in E. coli from pGEX-2T; (d) GST- 
CRABP II after incubation for 1 h at room temperature (control for 
track e); (e) GST-CRABP II digested with an excess of thrombin (5 
U/30 ,ug protein) for 1 h at room temperature; (M) marker proteins: 
1, phosphorylase b (M, 94 400); 2, BSA (M, 66 200); 3, ovalbuman (M, 
45 000); 4, bovine carbonic anhydrase (M, 31 000); 5, soybean trypsin 
inhibitor (M, 21 500); 6, lysozyme (M, 14 400). 
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Excitation wavelength Emission wavelength 
Fig. 2. Fluorescence xcitation (A) and emission (B) spectra for GST- 
CRABP II fusion protein (a,b, nominally 1 PM), thrombin-cleaved 
CRABP II (c,d, 0.2 PM), and GST (e,f, 2 ,uM), in the presence (b,d 
and f) and absence (a,c and e) of 0.3 PM all trans-retinoic acid. 
the second position of codon 71, resulting in a 
Glu+Gly amino acid substitution, and a C instead of 
T at the third base of codon 129 with no change in 
amino acid sequence. Human CRABP II consists of 138 
amino-acid residues and has a predicted M, = 15 700 
[3,41. 
Insertion of the CRABP II coding sequence into 
pGEX-2T, in-frame with the GST gene, resulted in the 
production of a fusion protein of apparent M, 43 400 
in IPTG-induced cells carrying the pGCRABP2 plas- 
mid. GST expressed in E. coli from pGEX-2T has an 
apparent M, of 27,500 [20] (Fig. 1) and the siie of fusion 
protein in pG-CRABP2 transformants was therefore 
consistent with expression of a full-length GST-CRABP 
II fusion protein. A single step, affinity gel purification 
of lysates from cultures expressing pGEX-2T or pG- 
CRABP,2 yielded the M, 27 500 or M, 43,400 GST- 
CRABP II proteins, respectively, as the major products 
with only minor contamination with other proteins 
(Fig. 1). The yield of GST-CRABP II was 2.5-3.5 mg 
* 1-l culture. Cleavage of the GST-CRABP II protein 
bound to the affinity gel produced three closely spaced 
protein bands in the eluate, with the larger band having 
an apparent M, of 15 200, similar to that expected for 
human CRABP II (Fig. 1). The smaller cleavage prod- 
ucts (apparent M, 14 400 and 13 800) may have resulted 
from partial cleavage within CRABP II at arginine res- 
idues 112 and 133 towards the carboxy-terminus of the 
protein. 
3.2. Binding of all trans-retinoic acid to GST-CRABP II 
fusion protein 
The binding of all trans-retinoic acid to GST-CRABP 
II fusion protein was assessed by fluorimetry. Excita- 
tion and emission spectra showed that adding all trans- 
retinoic acid to the fusion protein produced an in- 
creased emission at 475 nm with excitation wavelengths 
of 350-360 nm, consistent with the specific binding of 
retinoic acid (Fig. 2). Similar changes were observed 
after adding all trans-retinoic acid to CRABP II eluted 
from the affinity gel after cleavage with thrombin (Fig. 
2). Conversely, no changes in excitation or emission 
spectra were produced by adding retinoic acid to GST 
protein alone (Fig. 2). HPSEC analysis of the fusion 
protein after incubation with all tram [l 1, 12-3H]retinoic 
E 
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$ 200 
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-u 0 1 
543210 
time (minutes) 
Fig. 3. HPSEC of’06 ,ug GST-CRABP II after incubation with 8 nM 
all tranr-[1 ,12-3H]retinoic acid in the presense (0) and absence (0) of 
a 200-fold excess of unlabelled retinoic acid. Before injection onto the 
column, free [3Hhetinoic acid was removed by treating the fusion 
protein (6 jfg in 200 ,ul8 nM [‘Hhetinoic acid) with an equal volume 
of dextran-coated charcoal [24] and 40 ,uI of the supematant injected. 
Peak (a), eluted in the excluded volume at 2.4 min, presumably repre- 
sents high molecular weight aggregates; the major peak (b) at 3.8 min 
was eluted at the position expected for a M, 43 400 protein, Peak(s 
at 4.5-4.9 min represent free retinoic acid released from GST-CRAB J 
II during HPSEC. Marker proteins are IgG (ig, I@ 150 OO!& pvalbu- 
min (ov, M, 45 000), myoglobin (myo. M, 17 000) and cyanoca- 
balamin (cy, M, 1350). 
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Fig. 4. Fluorimetric titration (350 nm excitation, 475 nm emission) of 
0.8 PM GST-CRABP II (0) and GST (0) with all trans-retinoic acid. 
(A) Fluorescence intensity (arbitrary units). To illustrate the trend of 
the data, 1st and 2rd order regression equations have been fitted to 
the GST and GST-CRABP II data, respectively. (B) Plot of aP,, vs. 
(a/l-a)& for the GST-CRABP II data in A. F,,,, is 57.35 and from 
linear regression, the slope is 0.959, y-intercept is -0.216 and Kd 
22.5 nM. (C) Fluorescence intensity after adding increasing amounts 
of GST-CRABP II to 2 ml of 0.8 PM all rrans-retinoic acid in 50 mM 
Tris-HCl, pH 7.5. 
in the presence or absence of a 200-fold excess of unla- 
belled retinoic acid gave a spe&c binding peak at a 
position corresponding to the size of the fusion protein 
(Fig. 3). These data demonstrate that the CRABP II 
sequence of GST-CRABP II fusion protein specifically 
binds retinoic acid. 
Titration of GST-CRABP II fusion protein with all 
trans-retinoic acid gave increasing fluorescence until the 
protein was saturated (Fig. 4A). In the presence of ex- 
cess all trans-retinoic acid, fluorescence intensity was 
directly proportional to the amount of fusion protein 
added (Fig. 4C). The equilibrium dissociation constant 
(&) was estimated from fluorimetric titrations to be 
14.2 + 6.5 nM (95% confidence limits, n = 11 separate 
experiments, range 3-36.6 nM). GST protein alone 
showed no evidence for binding from fluorimetric titra- 
tion (Fig. 4A). CRABP II cleaved from the fusion pro- 
tein with thrombin had a similar Kd for retinoic acid to 
the intact fusion protein (Fig. 5). The effect of thrombin 
on binding activity was also investigated by incubating 
50 I I I I 
Al 
40 - 
0.00 0.05 0.10 0.15 0.20 0.25 
Retinoic acid (PM) 
7C 
6 
S 
- 5 
x 
p. 0 4 
8 
3 
2 
1 
0 
0 1 2 3 
(a/l--)Ro x 1 o7 
Fig. 5. Fluorimetric titration (350 nm excitation, 475 mn emission) of 
GST-CRABP II and thrombin-cleaved CRABP II. (A) Fluorescence 
intensity of 0.5 PM GST-CRABP II cleaved by thrombin (5 U, 1 h at 
room temperature, 0) and 0.5 pM GST-CRABP II incubated in the 
absence of thrombin (control, l ) with increasing all trans-retinoic acid 
concentrations. SDS-PAGE analysis of GST-CRABP II after cleave 
age is shown in Fig. 1, tracks d and e. (B) Plots of UP,, vs. (a/l-u)& 
for the data in A (0, thrombincleaved GST-CRABP II, & 1.2 nM; 
n , control intact GST-CRABP II, K,, 3.1 nM), and for 0.3 PM GST- 
CRABP II (0, & 10.8 nM) and 0.2 PM purifkd, thrombincleaved 
CRABP II (Fig. 2) (0, Kd 13.95 n&I) titrated against all trans-retinoic 
acid in a separate xperiment. 
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30 pug of GST-CRABP II for 1 h at room temperature 
with 5 U thrombin in 100 ,ul buffer C; a parallel, control 
incubation contained fusion protein but no thrombin. 
At the end of the incubation, cleavage of fusion protein 
by thrombin was complete (Fig. 1) and resulted in a 
slight reduction in binding activity but without any sig- 
nificant change in Kd (Fig. 5). 
3.3. The relative binding of all trans- and 9-cis-retinoic 
acid to GST-CRABP II fusion protein 
In initial fluorimetric titration experiments with 9-cis- 
retinoic acid, plots of aP, vs. (all-a)&, were curvilin- 
ear, suggesting that cis+trans isomerization was oc- 
curing as titration progressed. To avoid this problem, 
increasing concentrations of either all trans- or 9-c& 
retinoic acid were added to a series of tubes, each con- 
taining GST-CRABP II protein, so that the fluores- 
cence intensity of each sample was measured once. 
These experiments (Fig. 6) showed that, by comparison 
with all trans-retinoic acid, 9-cis-retinoic acid bound 
very poorly to the fusion protein and the extent of bind- 
ing was too low to obtain a reliable Kd estimate. The 
binding characteristics of all trans-retinoic acid to GST- 
CRABP II was similar to experiments in which conven- 
tional titration was used (Fig. 6). 
4. DISCUSSION 
CRABP is closely related to a number of other intra- 
cellular hydrophobic-ligand binding proteins, including 
cellular retinol binding protein, myelin P2 protein and 
fatty-acid binding proteins (FABP). The crystal struc- 
ture of rat intestinal FABP (I-FABP) and myelin P2 
protein has been elucidated [21,22]. These proteins con- 
sist of 10 antiparallel p-strands forming a B-barrel struc- 
ture with two amino-terminal a-helices, and represent 
a structural paradigm for other members of this family. 
Arginine residues 112 and 133 of CRABP I protrude 
into the cavity of the predicted B-barrel and, from struc- 
tural similarities with ligand-protein interactions in I- 
FABP [21], may be important in determining ligand 
specificity [23]. These arginine residues are conserved in 
CRABP I and II, and the carboxy-terminal amino acid 
sequences are also very similar [4]. 
From ligand binding studies, CRABP II has been 
reported to have a lower affinity for all trans-retinoic 
acid than CRABP I [5,6]. The present data indicate a K, 
of 14.2 nM for the binding of all trans-retinoic acid to 
GST-CRABP II. This value is close to the 10 nM re- 
ported by Fiorella and Napoli [19] for bovine CRABP 
I expressed in E. coli, an estimate also obtained by 
fluorimetric titration. The fact that thrombin-cleaved 
GST-CRABP II had similar binding characteristics to 
the intact fusion protein suggests that the GST ‘leader’ 
sequence does not substantially interfere with the fold- 
ing of the CRABP II sequence to form a functional and 
accessible ligand binding pocket. The presence of a 
60 I I I 
0 
0 
01 
0.0 0.5 1 .o 1.5 
Retinoic acid (PM) 
Fig. 6. Fluorimetric titration (350 nm excitation, 475 nm emission) of 
0.6 PM GST-CRABP II in the presence of increasing amounts of all 
truns-retinoic acid (0) or 9-cis-retinoic acid (0). From plots of ccP,, vs. 
(all -a)&, (not shown), the Kd for all truns-retinoic acid in this exper- 
iment was 13.3 nM. For 9-d the Kd estimate was > 600 nM but the 
extent of binding was too low to obtain a more reliable estimate. 
Similar results were obtained in two independent experiments. 
glycine rather than a glutamic acid residue at position 
71 in the CRABP II coding sequence used to make the 
GST-CRABP II fusion protein will probably not affect 
binding affinity: this residue is at the start of the /?E- 
strand [21,22], well away from the ligand binding pocket 
and predicted entry portal [21], and is orientated away 
from the/?-barrel cavity [22]. Measurements of the affin- 
ity of CRABP for retinoic acid have, in the past, pro- 
duced a range of different values depending on the 
methodology used [24], and on present results it seems 
likely that CRABP I and II may have similar affinities 
for retinoic acid. 
9-cis-Retinoic acid may be at least as important, if not 
more so, than all trans-retinoic acid in animal develop- 
ment, yet binds very poorly to GST-CRABP II. Similar 
conclusions have been recently reported by Allenby et 
al. [25] for the binding of 9-cis-[3H]retinoic acid to mur- 
ine CRABP I and II over-expressed in COS-1 cells. The 
fact that all truns-retinoic acid binds to CRABP with 
high affinity whereas 9-cis-retinoic acid does not implies 
that there may be other, as yet unidentified, specific 
binding proteins for 9-cis-retinoic acid [2]. Further- 
more, CRABP I and II have different patterns of ex- 
pression [2,3], and this raises the issue of the functional 
significance of the two forms of CRABP. The ease with 
which GST-CRABP fusion proteins may be purified 
from bacterial ysates suggests that they may be power- 
ful tools for comparing the binding affinities of CRABP 
for different retinoids. 
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